Tyra Biosciences, Inc. Stock Price, News & Analysis

Tyra Biosciences (Nasdaq: TYRA), a clinical-stage biotechnology firm, announced its participation in key investor conferences. CEO Todd Harris will engage in a fireside chat at Cantor's The Future of Oncology Virtual Symposium on April 4, 2023, at 2:15 PM ET. He will also present at the Bank of America 2023 Healthcare Conference on May 11, 2023, at 9:35 AM PT. TYRA focuses on developing precision medicines targeting FGFR biology and utilizes its innovative SNÅP platform for drug design. For live updates and webcasts, visit the company's investor page.

Tyra Biosciences (TYRA) reported financial results for 2022 and highlighted key milestones. The company initiated patient dosing for TYRA-300 in the SURF301 oncology study and expanded its pipeline to treat achondroplasia. The FDA cleared the IND for TYRA-200's Phase 1 study, expected to begin in 2H 2023. For 2022, TYRA recorded a full-year net loss of $55.3 million, compared to $26.3 million in 2021. R&D expenses increased to $43 million, and the company maintains a strong cash position with $251.2 million available, ensuring over two years of runway for its development plans.

Tyra Biosciences (Nasdaq: TYRA) announced the expansion of TYRA-300's development into achondroplasia following promising preclinical results. The oral FGFR3 selective inhibitor exhibited significant growth and bone length increases in preclinical models, including a 17.6% increase in body length and notable femur and tibia length improvements. A Phase 2 clinical study is planned for 2024, addressing unmet medical needs in children with achondroplasia. Additionally, TYRA has received FDA clearance for a Phase 1 study of TYRA-200, aimed at advancing its pipeline. A conference call was held on March 1 to discuss these developments.

Tyra Biosciences (Nasdaq: TYRA), a precision oncology company, announced its participation in two upcoming investor conferences. CEO Todd Harris will engage in a fireside chat at the Cowen 43rd Annual Healthcare Conference on March 7, 2023, at 10:30 am ET. Additionally, he will provide a company overview virtually at the Oppenheimer 33rd Annual Healthcare Conference on March 15, 2023, at 12:00 pm ET. Live and archived webcasts can be accessed through the Investor section of the TYRA website. Tyra focuses on developing therapies to combat tumor resistance, utilizing its proprietary SNÅP platform to design selective inhibitors targeting FGFR.

Tyra Biosciences has initiated the SURF301 Phase 1/2 clinical study for TYRA-300, an oral FGFR3-selective inhibitor for metastatic urothelial carcinoma, marking a pivotal shift to a clinical-stage company. The first patient has been dosed, with an emphasis on addressing unmet needs in both FGFR resistant and naïve populations. The study aims to establish optimal dosing and evaluate preliminary antitumor activity. Results and updates will be shared as data matures, with further details available on their website.

Tyra Biosciences (Nasdaq: TYRA) announced its participation in key investor conferences on November 14 and 15-17, 2022. CEO Todd Harris will engage in fireside chats at both events, aiming to showcase the company's innovations in precision oncology. The H.C. Wainwright 3rd Annual Precision Oncology Virtual Conference will feature a chat available on demand, while the Jefferies London Healthcare Conference will include a live chat on November 15 at 10:50 am ET. Webcasts of these discussions will be accessible on the TYRA Investor section.

Tyra Biosciences, Inc. (TYRA) reported its third-quarter 2022 financial results, highlighting a net loss of $12.5 million, an increase from $6.6 million in Q3 2021. Research and development expenses rose to $10.9 million, compared to $5.5 million in the prior year. As of September 30, 2022, cash and cash equivalents stood at $263.2 million. The company is focused on advancing its pipeline, which includes the initiation of the SURF301 study for TYRA-300 and filing an IND for TYRA-200 by year-end 2022.

Tyra Biosciences (Nasdaq: TYRA) announced a leadership transition, with Esther van den Boom stepping down as Chief Financial Officer to become an advisor at the end of 2022. Alan Fuhrman will assume the CFO role on January 1, 2023. CEO Todd Harris praised van den Boom's contributions and expressed confidence in Fuhrman's experience guiding companies through growth phases, including clinical development. Fuhrman looks forward to advancing TYRA's precision oncology pipeline, particularly the FGFR-targeting therapies, including TYRA-300, which has received FDA IND clearance.

Tyra Biosciences (Nasdaq: TYRA) will present preclinical data on its FGFR1/2/3 inhibitor, TYRA-200, at the 34th EORTC-NCI-AACR Symposium in Barcelona, Spain, from October 26-28, 2022. The presentation is scheduled for October 26 and focuses on TYRA-200's effectiveness against FGFR2 fusions, molecular brake mutations, and gatekeeper resistance, with the aim of enhancing outcomes for cancer patients. This event is pivotal as the company seeks to advance its pipeline targeting critical genetic alterations affecting cancer treatment.